Artivion, Inc. reported a 14% increase in total revenues for the fiscal year ending December 31, 2025, reaching $441.3 million, compared to $388.5 million in 2024. The growth was primarily driven by a 29% rise in revenues from aortic stent grafts, which accounted for $159.4 million, and a 21% increase in On-X products, totaling $101.7 million. The company also noted a 4% increase in surgical sealants, contributing $76.6 million to the overall revenue. However, revenues from preservation services decreased by 3% to $95.5 million, attributed to a backlog of tissues resulting from a cybersecurity incident in 2024. The net income for the year was reported at $9.8 million, a significant recovery from a net loss of $13.4 million in the previous year.
In terms of operational developments, Artivion has made strategic advancements, including the acquisition of Ascyrus Medical LLC, which has enhanced its product offerings in the aortic repair market. The company also launched the AMDS hybrid prosthesis, which received a humanitarian device exemption from the FDA in December 2024, allowing for its commercial distribution in the U.S. prior to full approval expected in 2026. Additionally, Artivion began manufacturing and supplying PerClot hemostatic powder under a transitional agreement with Baxter, following the FDA's approval of its PMA in May 2023.
The company reported a total employee headcount of approximately 1,800 as of December 31, 2025, with a significant presence in Kennesaw, Georgia; Austin, Texas; and Hechingen, Germany. Artivion's global expansion efforts have been evident, with increased sales in international markets, particularly in Europe, the Middle East, and Africa, which saw a revenue increase of 13% year-over-year. The company has also focused on enhancing its product adoption rates and market share through strategic partnerships and product launches.
Looking ahead, Artivion anticipates continued growth driven by its commitment to innovation and expansion in the aortic repair market. The company plans to invest in research and development, with expenditures of approximately $31 million in 2025, representing 7% of total revenues. Artivion's management expressed confidence in its ability to meet operational liquidity needs over the next twelve months, supported by cash flows from operations and available credit facilities. However, the company remains cautious of potential risks, including supply chain disruptions and regulatory challenges, which could impact future performance.
About ARTIVION, INC.
Artivion, Inc. is a medical device company specializing in cardiac and vascular surgical solutions for aortic disease. Its key products include aortic stent grafts, On-X mechanical heart valves, and surgical sealants like BioGlue. With a focus on innovation and global expansion, Artivion targets cardiac and vascular surgeons. The company is pursuing new product development and regulatory approvals, enhancing its market presence in emerging regions like China and Brazil.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.